SecBot SecBot
SECBOTREPLAY Home › Report › LXRX

LXRX · Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a…

Lexicon Pharmaceuticals, Inc. · PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET

Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a Phase 1 clinical trial for LX9851, a first-in-class oral obesity candidate discovered by Lexicon. As a result, Lexicon earned a $10 million milestone payment and remains eligible for up to $1 billion in total milestones plus royalties on future sales.

  • Novo Nordisk initiated a Phase 1 study of LX9851, triggering a $10 million milestone payment to Lexicon.
  • Lexicon is eligible for up to $1 billion in total upfront and milestone payments, including a third $10 million milestone potentially this year.
  • LX9851 is a novel oral non-incretin drug targeting obesity with preclinical data showing enhanced weight loss when combined with semaglutide.
  • The Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics in 96 individuals with overweight or obesity, with completion expected in Q1 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access